Free tool
FAERS Monitor: Amondys 45
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213026 or its brand name (Amondys 45, Casimersen). Reports on generic versions are filed under their own applications.
Reports
986
Serious
166
17% of reports
Hospitalization
120
Death reported
11
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product dose omission issue282
- no adverse event188
- poor venous access125
- device issue94
- intentional dose omission81
- malaise48
- pyrexia46
- covid-1933
- illness31
- influenza24
- product distribution issue21
- cough20
- dehydration17
- pneumonia17
- fall16
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 20 |
| 2022 | 146 |
| 2023 | 250 |
| 2024 | 205 |
| 2025 | 200 |
| 2026 | 165 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,173 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| poor venous accessSignal | 125 | 260.8 | 221.2 | 31,722 |
| intentional dose omissionSignal | 81 | 60.8 | 49.3 | 4,695 |
| product distribution issueSignal | 21 | 48.4 | 31.7 | 926 |
| device issueSignal | 94 | 22.4 | 18.5 | 1,905 |
| no adverse eventSignal | 188 | 22.2 | 19.5 | 3,806 |
| product dose omission issueSignal | 282 | 20.5 | 18.6 | 5,273 |
| illnessSignal | 31 | 6.4 | 4.5 | 137 |
| influenzaSignal | 24 | 4.6 | 3.1 | 64 |
| covid-19Signal | 33 | 4.0 | 2.9 | 72 |
| pyrexiaSignal | 46 | 2.8 | 2.1 | 54 |
| dehydrationSignal | 17 | 2.7 | 1.7 | 17 |
| malaiseSignal | 48 | 2.3 | 1.8 | 36 |
| cough | 20 | 1.5 | 1.0 | 3 |
| pneumonia | 17 | 1.1 | 0.7 | 0 |
| fall | 16 | 1.0 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.